Objectives: Allergic rhinitis (AR) is increasingly recognized as a systemic inflammatory condition. While symptom scores are commonly used for disease monitoring, objective biomarkers to predict treatment outcomes remain limited. This study evaluated systemic inflammatory indices (neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyte ratio [PLR], systemic immune-inflammation index [SII], eosinophil count, and total immunoglobulin E [IgE]) as biomarkers in AR over 6 month follow-up.
Methods: This prospective cohort study enrolled 105 patients with moderate-to-severe persistent AR and 92 matched healthy controls. Baseline and 6 month measurements included complete blood count-derived indices and total serum IgE. Symptom severity was assessed using Total Nasal Symptom Score and visual analog scales. ROC analyses determined optimal cutoff values for predicting treatment response.
Results: At baseline, AR patients had significantly-higher NLR, PLR, SII, and eosinophil counts than controls (all P < .001). These indices declined significantly in parallel with symptom improvement. Baseline NLR >2.7 showed the strongest predictive value for nonresponse (sensitivity 84%, specificity 76%, OR 4.2). PLR >240, SII >1100, eosinophils >600/µL, and IgE >450 IU/mL were also associated with increased nonresponse risk. Total IgE remained stable and was not useful for short-term monitoring. A mixed-effects longitudinal model confirmed that reductions in NLR, PLR, and eosinophil count were significantly greater in AR patients than in controls, supporting that these biomarker changes were treatment related.
Conclusion: NLR, PLR, SII, and eosinophil count are promising biomarkers for monitoring disease activity and predicting treatment response in AR. NLR may serve as a simple, cost-effective tool for early risk stratification. These findings support integrating routine hematologic markers into clinical management of AR.
扫码关注我们
求助内容:
应助结果提醒方式:
